ETC
LYEL icon

Exchange Traded Concepts’s Lyell Immunopharma LYEL Stock Holding History

Exchange Traded Concepts’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,317
Closed -$133K – 1471
2025
Q1 		$133K Buy
12,317
+5,564
+82% +$68.2K ﹤0.01% 1068
2024
Q4 		$86.4K Hold
6,753
– – ﹤0.01% 1169
2024
Q3 		$186K Buy
6,753
+1,836
+37% +$54K ﹤0.01% 988
2024
Q2 		$143K Sell
4,917
-1,530
-24% -$72.8K ﹤0.01% 911
2024
Q1 		$288K Buy
6,447
+2,299
+55% +$98.4K 0.01% 816
2023
Q4 		$161K Buy
4,148
+1,052
+34% +$37.9K ﹤0.01% 821
2023
Q3 		$91K Buy
3,096
+909
+42% +$43.2K ﹤0.01% 935
2023
Q2 		$139K Buy
+2,187
New +$121K ﹤0.01% 865

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exchange Traded Concepts's LYEL Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 12,317 shares — an estimated $133K sold.

Exchange Traded Concepts first reported a position in LYEL in Q2 2023 and held it in 8 quarters. The position peaked at $288K in Q1 2024. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 12,317 Lyell Immunopharma shares in Q2 2025, an estimated $133K.
  • Exchange Traded Concepts first reported a position in Lyell Immunopharma in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Lyell Immunopharma position peaked at $288K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.